HEALER™ Technology Platform

HEALER = High Efficiency Amino Lipid Enabled Release

Using our HEALER technology, we develop innovative prescription drug products based on small molecule derivatives of n-3 and n-6 fatty acids and their proresolving lipid mediator metabolites to address new indications with significant unmet medical needs.

Historically, use of n-3 and n-6 fatty acids in the prescription drug arena has been limited by several factors including low bioavailability, poor stability, lack of intellectual property protection, and physico-chemical characteristics that are unsuitable for conventional oral and parenteral dosage forms. Application of HEALER is an efficient way to overcome these deficits to create new medicines with properties that enable new therapeutic indications with long-term, patent-protected commercial viability.

Proresolving lipid mediators (PLMs), including resolvins, protectins, lipoxins and maresins, represent a new class of potential therapeutic agents that occur endogenously but have not yet been developed into prescription drugs due to lack of intellectual property protection with respect to the natural entities. By delivering the endogenous entities with composition of matter patent protection and thus avoiding the need for major discovery programs to develop synthetic analogs, HEALER enables efficient development of first-in-class PLM drugs for treatment of major inflammatory diseases with low risk of off-target effects.

Learn more about our HEALER platform. »»